Affymax, (FRA:A5Y) Current Deferred Revenue : €0.00 Mil (As of Jun. 2014)

View and export this data going back to . Start your Free Trial

What is Affymax, Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Affymax,'s current deferred revenue for the quarter that ended in Jun. 2014 was €0.00 Mil.

Affymax, Current Deferred Revenue Historical Data

The historical data trend for Affymax,'s Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymax, Current Deferred Revenue Chart

Affymax, Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Current Deferred Revenue

Get a 7-Day Free Trial

49.37

13.98

Affymax, Quarterly Data
	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14
Current Deferred Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Affymax, Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Affymax,'s Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Affymax, (FRA:A5Y) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affymax, Inc. (FRA:A5Y) » Definitions » Current Deferred Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

630 Fifth Avenue, 2nd Floor, New York, NY, USA, 10020

Website

http://www.affymax.com

Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.

Affymax, (FRA:A5Y) Headlines

No Headlines